These experimental replicon shots are primary funded by BARDA with support from the Gates Foundation, who gave Arcturus Therapeutics a $928,563 grant in October 2024 to “improve understanding of durability of protection after administration of nucleic-acid based vaccines.”
Click Here for More Information
San Diego
California
United States
© Prepping Communities. This content is for informational purposes only and not professional advice. Use at your own risk.
Terms | Privacy | Guidelines